Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference

GlobeNewswire June 10, 2020

Ayisha Jeter Joins Arcutis as Vice President of Market Access

GlobeNewswire June 1, 2020

Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations

GlobeNewswire May 27, 2020

Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire May 12, 2020

Halley E. Gilbert Appointed to Arcutis Board of Directors

GlobeNewswire April 27, 2020

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

GlobeNewswire April 21, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

GlobeNewswire March 23, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

GlobeNewswire March 16, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

GlobeNewswire March 5, 2020

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting

GlobeNewswire March 3, 2020

Arcutis to Present at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 19, 2020

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

GlobeNewswire February 13, 2020

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 4, 2020